X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ACTAVIS (US) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ACTAVIS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
ACTAVIS
Dec-14
GLENMARK PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs99317,418-   
Low Rs72910,625-   
Sales per share (Unadj.) Rs325.53,136.6-  
Earnings per share (Unadj.) Rs39.3-391.4-  
Cash flow per share (Unadj.) Rs48.7287.8-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs159.26,803.1-  
Shares outstanding (eoy) m282.17265.90-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.5 59.2%   
Avg P/E ratio x21.9-35.8 -61.2%  
P/CF ratio (eoy) x17.748.7 36.3%  
Price / Book Value ratio x5.42.1 262.4%  
Dividend payout %5.10-   
Avg Mkt Cap Rs m242,9913,728,306 6.5%   
No. of employees `00013.021.6 60.0%   
Total wages/salary Rs m16,4080-   
Avg. sales/employee Rs Th7,083.938,611.5 18.3%   
Avg. wages/employee Rs Th1,265.40-   
Avg. net profit/employee Rs Th855.1-4,818.3 -17.7%   
INCOME DATA
Net Sales Rs m91,857834,009 11.0%  
Other income Rs m374-2,082 -18.0%   
Total revenues Rs m92,230831,927 11.1%   
Gross profit Rs m20,367107,140 19.0%  
Depreciation Rs m2,644180,593 1.5%   
Interest Rs m2,37326,306 9.0%   
Profit before tax Rs m15,724-101,841 -15.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-810-7,470 10.8%   
Tax Rs m3,827-5,236 -73.1%   
Profit after tax Rs m11,088-104,076 -10.7%  
Gross profit margin %22.212.8 172.6%  
Effective tax rate %24.35.1 473.4%   
Net profit margin %12.1-12.5 -96.7%  
BALANCE SHEET DATA
Current assets Rs m68,746439,416 15.6%   
Current liabilities Rs m27,027320,463 8.4%   
Net working cap to sales %45.414.3 318.4%  
Current ratio x2.51.4 185.5%  
Inventory Days Days8558 146.5%  
Debtors Days Days9666 144.1%  
Net fixed assets Rs m24,132101,841 23.7%   
Share capital Rs m2820-   
"Free" reserves Rs m44,6430-   
Net worth Rs m44,9251,808,934 2.5%   
Long term debt Rs m45,363947,917 4.8%   
Total assets Rs m117,6393,315,181 3.5%  
Interest coverage x7.6-2.9 -265.6%   
Debt to equity ratio x1.00.5 192.7%  
Sales to assets ratio x0.80.3 310.4%   
Return on assets %11.4-2.3 -487.8%  
Return on equity %24.7-5.8 -429.0%  
Return on capital %19.1-3.0 -635.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m48,0680-   
CASH FLOW
From Operations Rs m6,574143,216 4.6%  
From Investments Rs m-7,124-342,913 2.1%  
From Financial Activity Rs m5,432192,667 2.8%  
Net Cashflow Rs m1,992-7,030 -28.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: PLETHICO PHARMA  LUPIN LTD  FDC LTD.  ORCHID PHARMA LTD  SUVEN LIFE  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views On News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - UNICHEM LAB COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS